Margaret Burroughs

6.0k total citations · 1 hit paper
92 papers, 4.0k citations indexed

About

Margaret Burroughs is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Margaret Burroughs has authored 92 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Hepatology, 53 papers in Epidemiology and 30 papers in Infectious Diseases. Recurrent topics in Margaret Burroughs's work include Hepatitis C virus research (56 papers), Liver Disease Diagnosis and Treatment (22 papers) and Hepatitis B Virus Studies (20 papers). Margaret Burroughs is often cited by papers focused on Hepatitis C virus research (56 papers), Liver Disease Diagnosis and Treatment (22 papers) and Hepatitis B Virus Studies (20 papers). Margaret Burroughs collaborates with scholars based in United States, France and Spain. Margaret Burroughs's co-authors include Clifford A. Brass, Janice K. Albrecht, Navdeep Boparai, Bruce R. Bacon, Fred Poordad, Stuart C. Gordon, Rafael Esteban, Heather L. Sings, Elaine Tuomanen and John M. Vierling and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Margaret Burroughs

89 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

2011 1.2k citations Bruce R. Bacon, Stuart C. Gordon et al. New England Journal of Medicine profile →

Peers

Margaret Burroughs

EPIDE

HEPAT

MICRO

Aril Frydén Sweden

Juan Ignacio Esteban Spain

William L. Irving United Kingdom

Andrzej Horban Poland

Juan González‐Lahoz Spain

F. Lunel France

Takeshi Tanaka Japan

Toshio Shikata Japan

G. Filice Italy

Janice A. Kolberg United States

Aril Frydén Sweden

Margaret Burroughs

2.0k ×0.8

EPIDE

1.5k ×0.6

HEPAT

402 ×0.4

191 ×0.6

161 ×0.5

MICRO

Citations per year, relative to Margaret Burroughs Margaret Burroughs (= 1×) peers Aril Frydén

Countries citing papers authored by Margaret Burroughs

Since Specialization

Citations

This map shows the geographic impact of Margaret Burroughs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret Burroughs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret Burroughs more than expected).

Fields of papers citing papers by Margaret Burroughs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret Burroughs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret Burroughs. The network helps show where Margaret Burroughs may publish in the future.

Co-authorship network of co-authors of Margaret Burroughs

This figure shows the co-authorship network connecting the top 25 collaborators of Margaret Burroughs. A scholar is included among the top collaborators of Margaret Burroughs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaret Burroughs. Margaret Burroughs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brown, Robert S., Michelle A. Collins, Simone I. Strasser, et al.. (2022). Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension. Infectious Diseases and Therapy. 11(2). 913–924. 1 indexed citations

Gordon, Stuart C., Eric M. Yoshida, Eric Lawitz, et al.. (2013). Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Alimentary Pharmacology & Therapeutics. 38(1). 16–27. 17 indexed citations

Barnard, Richard J. O., John A. Howe, Robert A. Ogert, et al.. (2013). Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology. 444(1-2). 329–336. 54 indexed citations

Gordon, Stuart C., K. Rajender Reddy, Ira M. Jacobson, et al.. (2013). Boceprevir Plus Peginterferon α-2b/Ribavirin in Chronic Hepatitis C Genotype 1. Journal of Clinical Gastroenterology. 48(5). 435–443. 3 indexed citations

Bruno, Savino, John M. Vierling, Rafael Esteban, et al.. (2012). Efficacy and safety of boceprevir plus peginterferon–ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. Journal of Hepatology. 58(3). 479–487. 40 indexed citations

Poordad, Fred, Jean–Pierre Bronowicki, Stuart C. Gordon, et al.. (2012). Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir. Gastroenterology. 143(3). 608–618.e5. 150 indexed citations

Poynard, Thierry, Jordi Bruix, Eugene R. Schiff, et al.. (2012). Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: A randomized study. Journal of Hepatology. 58(3). 452–459. 6 indexed citations

Flamm, Steven L., Eric Lawitz, Ira M. Jacobson, et al.. (2012). Boceprevir With Peginterferon Alfa-2a–Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection. Clinical Gastroenterology and Hepatology. 11(1). 81–87.e4. 49 indexed citations

Poordad, F., E.J. Lawitz, K. Rama Reddy, et al.. (2012). 1419 A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN. Journal of Hepatology. 56. S559–S559. 33 indexed citations

10.

Zeuzem, Stefan, John M. Vierling, Rafael Esteban, et al.. (2011). 484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN. Journal of Hepatology. 54. S198–S199. 30 indexed citations

11.

Brass, Clifford A., Richard J. O. Barnard, John A. Howe, et al.. (2011). 1194 SUSTAINED VIROLOGIC RESPONSE AND BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS OBSERVED IN PATIENTS INFECTED WITH HCV GENOTPYPE 1A/1B WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN. Journal of Hepatology. 54. S471–S472. 9 indexed citations

12.

Bacon, Bruce R., Stuart C. Gordon, Eric Lawitz, et al.. (2011). Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection. New England Journal of Medicine. 364(13). 1207–1217. 1229 indexed citations breakdown →

13.

Bruix, Jordi, Thierry Poynard, Massimo Colombo, et al.. (2011). Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C. Gastroenterology. 140(7). 1990–1999. 74 indexed citations

14.

Burroughs, Margaret, et al.. (2002). Cytomegalovirus matching does not predict symptomatic disease in intestinal transplantation. Transplantation Proceedings. 34(3). 946–947. 6 indexed citations

15.

Burroughs, Margaret, et al.. (2001). The Role of Quantitative Epstein‐Barr Virus Polymerase Chain Reaction and Preemptive Immunosuppression Reduction in Pediatric Liver Transplantation: A Preliminary Experience. Journal of Pediatric Gastroenterology and Nutrition. 33(4). 445–449.

16.

Burroughs, Margaret, et al.. (1995). Effect of thalidomide on the inflammatory response in cerebrospinal fluid in experimental bacterial meningitis. Microbial Pathogenesis. 19(4). 245–255. 23 indexed citations

17.

Burroughs, Margaret, Eva Rozdzinski, Sibyl P. M. Geelen, & Elaine Tuomanen. (1993). A structure-activity relationship for induction of meningeal inflammation by muramyl peptides.. Journal of Clinical Investigation. 92(1). 297–302. 56 indexed citations

18.

Rozdzinski, Eva, Tara N. Jones, W. Neal Burnette, Margaret Burroughs, & Elaine Tuomanen. (1993). Antiinflammatory Effects in Experimental Meningitis of Prokaryotic Peptides that Mimic Selectins. The Journal of Infectious Diseases. 168(6). 1422–1428. 29 indexed citations

19.

Burroughs, Margaret, Carmen Cabellos, S. Prasad, & Elaine Tuomanen. (1992). Bacterial Components and the Pathophysiology of Injury to the Blood-Brain Barrier: Does Cell Wall Add to the Effects of Endotoxin in Gram-Negative Meningitis?. The Journal of Infectious Diseases. 165(Supplement 1). S82–S85. 32 indexed citations

20.

Saukkonen, Kapo, et al.. (1991). Integrin-mediated localization of Bordetella pertussis within macrophages: role in pulmonary colonization.. The Journal of Experimental Medicine. 173(5). 1143–1149. 153 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact